All conditions

Cystic Fibrosis

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1446
Trials on record
132
Recruiting now
3
Australian sites
4
Phase 3 trials
8
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Cystic Fibrosis →

Get alerts when Cystic Fibrosis trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Cystic Fibrosis

Cystic Fibrosis (CF) is a genetic condition that affects the way the body produces mucus. In people with CF, the mucus in the body is much thicker and stickier than normal. This thick mucus can build up in the lungs, making it harder to breathe and increasing the risk of infections. It can also affect the digestive system, making it more difficult for the body to absorb nutrients from food properly. CF is caused by changes in a gene called the CFTR gene, and a person is born with it — it is not something that can be caught from another person.

In Australia, CF is one of the most common serious genetic conditions, affecting around 3,500 people. It occurs across all backgrounds, but is most commonly seen in people of European ancestry. For someone to have CF, they need to inherit a changed copy of the CFTR gene from both parents. Many parents have no idea they carry the gene until a child is diagnosed. In Australia, most babies are now identified through the newborn screening program, which means many children are diagnosed very early in life.

Treatment for CF in Australia is managed by specialist CF teams, usually based at major hospitals. Care typically involves a combination of regular physiotherapy to help clear mucus from the lungs, medications to help keep the airways open, and enzyme supplements taken with meals to help with digestion. Many people with CF have several clinic appointments throughout the year to keep a close eye on their health. Over the past decade, newer medications have become available in Australia that target the underlying cause of CF in many people, and these have made a significant difference to the lives of those who are eligible for them. A specialist CF team will work with each person to figure out what approach suits their individual situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Cystic Fibrosis in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Cystic Fibrosis

8 medicines listed on the PBS for Cystic Fibrosis. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 8 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Dornase alfa Pulmozyme Cystic fibrosis AU$745.49 Streamlined authority
elexacaftor + tezacaftor + ivacaftor (&) ivacaftor Trikafta Cystic fibrosis AU$20306.25 Authority required
Ivacaftor Kalydeco Cystic fibrosis AU$20306.25 Authority required
Lumacaftor + ivacaftor Orkambi Cystic fibrosis AU$16921.88 Authority required
Mannitol Bronchitol Cystic fibrosis AU$447.3 Streamlined authority
protein hydrolysate formula with medium chain triglycerides Aptamil Gold+ Pepti-Junior Cystic fibrosis AU$21.5 Streamlined authority
Vanzacaftor + tezacaftor + deutivacaftor Alyftrek Cystic fibrosis AU$21375 Authority required
tezacaftor + ivacaftor (&) ivacaftor Symdeko Cystic fibrosis - homozygous for the F508del mutation AU$18952.5 Authority required
tezacaftor + ivacaftor (&) ivacaftor Symdeko Cystic fibrosis - one residual function (RF) mutation AU$18952.5 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Cystic Fibrosis currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Cystic Fibrosis.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Cystic Fibrosis by country. Australia is highlighted.

Showing the top 10 of 40 countries with trial sites.

Clinical trials for Cystic Fibrosis

Showing 155 of 155 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00112359 · Gilead Sciences Phase 3 · 4 countries Completed
Completed Phase 3 Est. completion 1 April 2007
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - You have a confirmed diagnosis of cystic fibrosis (CF), shown by a sweat test result, a genetic test finding two known CF gene changes, or an abnormal test of nasal airway function. - A bacteria called *Pseudomonas aeruginosa* was found in your sputum (mucus you cough up) or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00388505 · Novartis Pharmaceuticals Phase 3 · 14 countries Completed
Completed Phase 3 Est. completion 1 March 2009
🇦🇺 AU🇨🇦 CA🇨🇱 CL🇨🇴 CO🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇱 IL +6 more

**Who might be able to join this trial:** - You have a confirmed diagnosis of cystic fibrosis. - You are male or female and at least 6 years old at the time of screening. - Your lung function test (measuring how much air you can breathe out in one second) falls within a specific moderate range — not too low and not too...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00645788 · Bayer Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 1 January 2011
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇩🇪 DE🇮🇱 IL🇳🇴 NO🇸🇪 SE🇬🇧 GB +1 more

**Who might be able to join this trial:** - You (or your legal guardian) must be willing and able to sign a consent form agreeing to take part in the study - You must be between 12 and 17 years old, or 18 years old or older - You must have a confirmed diagnosis of Cystic Fibrosis (CF), shown by specific test results a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00737100 · Boehringer Ingelheim Phase 2 · 11 countries Completed
Completed Phase 2 Est. completion 1 April 2010
🇦🇺 AU🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇵🇹 PT +3 more

Who might be able to join this trial: - Both men and women can apply. - You must have a confirmed diagnosis of Cystic Fibrosis, shown either by a sweat chloride test or by having two identified genetic mutations related to CF. - Your lung function (measured by a breathing test called FEV1) must be at least 25% of the n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00909727 · Vertex Pharmaceuticals Incorporated Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 1 November 2010
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇪 IE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You weigh at least 15 kg (about 33 pounds) - You have a confirmed diagnosis of cystic fibrosis (CF) with a specific genetic mutation called G551D in at least one copy of the relevant gene - Your lung function test (measuring how much air you can breathe out in one second) fal...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00930982 · Bayer Phase 2 · 6 countries Completed
Completed Phase 2 Est. completion 1 September 2010
🇦🇺 AU🇩🇪 DE🇪🇸 ES🇸🇪 SE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with bronchiectasis (a lung condition where the airways are permanently widened) that is either of unknown cause or happened after a lung infection, and is *not* related to cystic fibrosis. - Your lung condition has been stable and your trea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01225211 · Vertex Pharmaceuticals Incorporated Phase 2 · 7 countries Completed
Completed Phase 2 Est. completion 1 April 2014
🇦🇺 AU🇧🇪 BE🇫🇷 FR🇩🇪 DE🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have a confirmed diagnosis of cystic fibrosis (CF) - You carry a specific CF gene change called F508del on at least one copy of your CF gene - Your lung function test result (called FEV1) meets the required level for the group (cohort) you would be joining — either at or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01537666 · Savara Inc. Phase 1 · 1 country Completed
Completed Phase 1 Est. completion 1 March 2012
🇦🇺 AU

**Who might be able to join this trial:** **For healthy volunteers:** - Men aged 18 to 50 years old in good health - People who are able to communicate with the study team and are willing to sign a consent form - People who are able and willing to attend all required study visits and follow the study rules - People wh...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01931839 · Vertex Pharmaceuticals Incorporated Phase 3 · 15 countries Completed
Completed Phase 3 Est. completion 1 April 2016
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE +7 more

**Who might be able to join this trial:** - You must have signed a consent form agreeing to take part (and a separate assent form if applicable). - To join the **Part A Treatment Group**: You must have completed 24 weeks of treatment in a related study called Study 103 or Study 104, and be willing to continue into thi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02516410 · Vertex Pharmaceuticals Incorporated Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 7 June 2016
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇫🇷 FR🇮🇱 IL🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - You have a confirmed diagnosis of cystic fibrosis (CF), shown by a specific sweat test result that measures the amount of salt (chloride) in your sweat, with a result of 60 or above. - You carry one copy of a specific CF gene change called F508del, plus a second CF gene change th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02730208 · Vertex Pharmaceuticals Incorporated Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 July 2018
🇦🇺 AU

**Who might be able to join this trial:** - You must have cystic fibrosis (CF) caused by having two copies of a specific gene change called "F508del" (one inherited from each parent) - You must have an official diagnosis of cystic fibrosis - Your lung function test results (measuring how much air you can breathe out fo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02875366 · Vertex Pharmaceuticals Incorporated Phase 4 · 2 countries Completed
Completed Phase 4 Est. completion 1 September 2017
🇦🇺 AU🇬🇧 GB

Who might be able to join this trial: - You have two copies of a specific gene change called F508del in the CF (cystic fibrosis) gene - You have a confirmed cystic fibrosis diagnosis, shown by a sweat test result of 60 mmol/L or higher - Your CF is considered stable, as judged by the doctor running the trial - Your lun...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03460990 · Vertex Pharmaceuticals Incorporated Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 26 September 2018
🇦🇺 AU🇩🇪 DE🇮🇪 IE🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must have two copies of a specific cystic fibrosis gene change called "F508del" (one inherited from each parent) - Your lung function test result (measuring how much air you can breathe out in one second) must fall within a specific range — not too low and not too high — base...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03559062 · Vertex Pharmaceuticals Incorporated Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 21 December 2018
🇦🇺 AU🇧🇪 BE🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE🇵🇱 PL🇨🇭 CH +1 more

**Who might be able to join this trial:** - You must have a specific genetic makeup related to cystic fibrosis — either two copies of the F508del gene mutation, or one copy of F508del plus another specific type of mutation (confirm with trial site for exact mutation details) - Your lung function test result (measuring...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03691779 · Vertex Pharmaceuticals Incorporated Phase 3 · 5 countries Completed
Completed Phase 3 Est. completion 7 August 2020
🇦🇺 AU🇨🇦 CA🇮🇪 IE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You carry a specific gene change related to cystic fibrosis called "F508del" — either two copies of it, or one copy alongside certain other gene changes (confirm with trial site) - Your lung function test result (measuring how much air you can breathe out in one second) is at...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04043806 · Vertex Pharmaceuticals Incorporated Phase 3 · 11 countries Completed
Completed Phase 3 Est. completion 14 December 2022
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇩🇪 DE🇮🇪 IE🇮🇱 IL🇵🇱 PL🇪🇸 ES +3 more

Who might be able to join this trial: - You are currently taking part in a specific related clinical study called VX17-659-105 (also known as NCT03447262) Who may not be able to join: - You had a bad reaction to the study drug during the VX17-659-105 study that the doctors believe could put you at extra risk if you co...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04058353 · Vertex Pharmaceuticals Incorporated Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 12 June 2020
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇪 IE🇮🇱 IL +5 more

Who might be able to join this trial: - You have a confirmed diagnosis of cystic fibrosis (CF) and carry one copy of a specific gene change called F508del, along with a second specific type of gene change (called a "gating" or "residual function" mutation - Your lung function test results (a breathing test called FEV1)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04353817 · Vertex Pharmaceuticals Incorporated Phase 3 · 10 countries Completed
Completed Phase 3 Est. completion 17 May 2021
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇱 IL🇳🇱 NL🇪🇸 ES +2 more

**Who might be able to join this trial:** - You carry one copy of a specific gene change called F508del (meaning you have one F508del mutation and one other type of mutation) (confirm with trial site) - Your lung function test result (measuring how much air you can breathe out in one second) is 70% or above of the expe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04599465 · Vertex Pharmaceuticals Incorporated Phase 3 · 7 countries Completed
Completed Phase 3 Est. completion 14 July 2022
🇦🇺 AU🇧🇪 BE🇨🇿 CZ🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES

**Who might be able to join this trial:** - You carry a specific combination of cystic fibrosis gene changes — one copy of the "F508del" mutation and one copy of a so-called "minimal function" mutation - Your lung function test result (measuring how much air you can breathe out in one second) is at least 30% of what wo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05802264 · Cystetic Medicines, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** *For Parts A and B (healthy volunteers):* - People who have signed and received a copy of the approved consent form - People aged 18 to 55 years old - People with a body weight in proportion to their height, with a BMI between 18 and 32 - People with healthy lung function, mea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07035990 · Sionna Therapeutics Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇦🇺 AU

**Who might be able to join this trial:** - Adults between 18 and 55 years old (inclusive) at the time of giving consent, who are generally healthy - People who weigh at least 45 kg and have a body mass index (BMI) between 18.0 and 32.0 at the screening visit - People who are willing to avoid alcohol, caffeine, smokin...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07048262 · CSL Behring Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 28 February 2028
🇦🇺 AU🇯🇵 JP

Who might be able to join this trial: - Adults aged between 18 and 85 years old. - People who have been diagnosed with non-cystic fibrosis bronchiectasis (a lung condition where the airways are permanently widened), confirmed by a chest CT scan reviewed by a radiologist — a scan from within the past 12 months is accept...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03460704 · Zambon SpA Phase 3 · 12 countries Terminated
Terminated Phase 3 Est. completion 15 March 2022
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR🇮🇱 IL🇮🇹 IT +4 more

Who might be able to join this trial: - People who are able and willing to give their written consent after having the study fully explained to them - People aged 18 years or older, of any gender - People who have been diagnosed with non-cystic fibrosis bronchiectasis (a lung condition causing widened, damaged airways)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05006573 · AstraZeneca Phase 3 · 16 countries Terminated
Terminated Phase 3 Est. completion 16 April 2024
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇨🇳 CN🇩🇰 DK🇩🇪 DE🇮🇳 IN🇮🇹 IT +8 more

**Who might be able to join this trial:** - You are 18 years of age or older - A doctor has diagnosed you with non-cystic fibrosis bronchiectasis (a lung condition), and this has been confirmed by a CT scan - You have had 2 or more bronchiectasis flare-ups (worsening of symptoms requiring treatment) within the past ye...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00416182 · University of Vermont Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 1 June 2012
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cystic fibrosis through medical tests and lab results - You are 5 years old or older - Your lung function test shows that you can breathe out at least 40% of the normal expected amount in one second (confirm with trial site) - You have had sinus surge...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05531630 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country By Invitation
By Invitation Not Applicable Est. completion 1 August 2023
🇧🇪 BE

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with cystic fibrosis - You regularly attend follow-up appointments at UZ Leuven (a hospital in Belgium) - You have been diagnosed with a long-term sinus condition (with or without nasal polyps), and at least one of your si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00943514 · National Heart, Lung, and Blood Institute (NHLBI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - Children aged 5 and older, as well as adults of any age, who have been referred to the NIH with long-term or repeated respiratory infections - Both males and females of any race or ethnicity are welcome to apply - People whose main condition is bronchiectasis (a lung conditi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01401998 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a liver or kidney fibrocystic disease (a condition where fluid-filled cysts form in the liver or kidneys), confirmed through medical records, imaging scans, a tissue sample, autopsy findings, or genetic testing. Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01851642 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 July 2032
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have signed a consent form agreeing to take part in the study - If you are a woman who could become pregnant, you have tested negative for pregnancy - Your hemoglobin (a measure of healthy red blood cells) is above 12.5 g/dl on the day y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01851694 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: **For people with cystic fibrosis:** - A confirmed diagnosis of cystic fibrosis, based on a sweat test or genetic (CFTR) mutation analysis following Cystic Fibrosis Foundation diagnostic standards - Age 18 or older at the time of signing consent - Pancreatic insufficiency (the pan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01852448 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

Who might be able to join this trial: - People who are older than 2 years of age - People who have been diagnosed with Cystic Fibrosis - For people under 18 years old, a parent or guardian must give their permission (informed consent), and the child should also agree to take part if they are old enough to do so Who ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02270476 · Heidelberg University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇩🇪 DE

**Who might be able to join this trial:** - People who have been newly diagnosed with Cystic Fibrosis (CF), confirmed by at least one of three accepted methods: a sweat chloride test result of 60 or above, two CF-causing gene changes, or specific electrical measurements in the nose or rectum that are typical of CF. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02641769 · Stem Cells Arabia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2030
🇯🇴 JO

Who might be able to join this trial: - Men who have been diagnosed as infertile and have had it confirmed that they produce no sperm due to a production problem in the testicles (rather than a blockage) Who may not be able to join: - Men whose lack of sperm is caused by a blockage in the reproductive tract (rather th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02740868 · The Hospital for Sick Children Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged 8 years old or older, both male and female - People who have never smoked - People with cystic fibrosis (CF) or asthma who have a formal diagnosis and whose symptoms are at their usual stable level (confirm with trial site) - People whose lung function test resul...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02965326 · Hôpital Necker-Enfants Malades Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇫🇷 FR

**Who might be able to join this trial:** - People with cystic fibrosis who are taking a CFTR modulator medication (either Ivacaftor alone, or Ivacaftor combined with Lumacaftor) - People with cystic fibrosis who are not taking any CFTR modulator medication - People who were thought to possibly have cystic fibrosis, bu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03052283 · Medizinische Hochschule Brandenburg Theodor Fontane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

Who might be able to join this trial: **For people with Cystic Fibrosis (CF):** - A diagnosis of CF confirmed by a sweat chloride test result above 60 mEq/L, and/or the detection of two CF-causing gene changes alongside signs of organ involvement **For healthy volunteers (control group):** - People who are a similar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03587961 · George Solomon Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cystic fibrosis (CF) - People aged 6 years or older - People who have a specific CF gene mutation (CFTR mutation) that the study investigators believe may respond to approved CF medications called correctors or potentiators - People who hav...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT03670472 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - People aged 8 years or older, both male and female - People who have cystic fibrosis caused by a specific type of genetic change called a nonsense mutation, present on both copies of the CFTR gene - People whose CFTR gene type has already been identified through genetic testing -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03839992 · Gelb, Arthur F., M.D. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 April 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cystic fibrosis (either carrying one or two copies of the gene change that causes it) - Your routine breathing test results (taken before using an inhaler to open the airways) are normal, including all three measurements checked: how much air you can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03925194 · Heidelberg University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 or older (and possibly young people aged 12–17 if later study results support expanding the trial to this age group) - People who are able to give their own consent, or whose legal guardians are able to give consent on their behalf - People who speak enough Ge...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04002882 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** *For people with cystic fibrosis (CF):* - A confirmed CF diagnosis, based on a sweat test and/or genetic testing that shows two disease-causing mutations - Aged 16 years or older - Health has been stable, meaning no changes to medications or treatment for at least 21 days befo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04026360 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2050
🇨🇭 CH

Who might be able to join this trial: - The patient must be an infant or child who has been diagnosed with cystic fibrosis (CF) through newborn screening - The patient must be 18 years old or younger - Written permission (consent) must be provided by the patient and/or their parent or guardian Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04137133 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇫🇷 FR

**Who might be able to join this trial:** - Infants who have recently been diagnosed with classic cystic fibrosis, confirmed by symptoms, at least two positive sweat tests, and/or two specific gene mutations of a certain type (Class I to III) - Children who have not been found to have a bacteria called *Pseudomonas aer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04157361 · The Institute of Molecular and Translational Medicine, Czech Republic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇿 CZ

**Who might be able to join this trial:** - Children or adults who have moderate or IgE-mediated asthma (a type of asthma triggered by the immune system's allergic response) - Children or adults who have cystic fibrosis - Children or adults who are generally healthy and do not have any lung conditions (participating as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04294043 · Chris Goss Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2027
🇺🇸 US

**Who might be able to join this trial:** *For people with CF who have never been treated for NTM (Treatment-Naïve group):* - People of any gender aged 18 or older at the first study visit who are willing and able to sign a consent form - People who are willing and able to follow the study schedule and meet all study...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04469439 · University of California, Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 99 years old - You have been diagnosed with cystic fibrosis, confirmed through genetic testing along with a doctor's assessment and/or a sweat test - You have been diagnosed with chronic rhinosinusitis (long-term sinus inflammation/infection), confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04509050 · Sonya Heltshe Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** **Part A:** - Children who are less than 10 years old at their first study visit - Children who have been diagnosed with cystic fibrosis (CF) **Part B:** - Children who either took part in Part A, OR are less than 7 years old at their first study visit - Children who have bee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04530383 · University of Kansas Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are over 18 years old and have been diagnosed with cystic fibrosis (CF) - You have been taking one of these CF medications for at least 30 days before the start of the study: ivacaftor, elexacaftor/tezacaftor/ivacaftor, or vanzacaftor/tezacaftor/deutivacaftor - You have b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04538859 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 August 2027
Hong Kong

Who might be able to join this trial: - People who are 18 years of age or older - People whose condition has been stable for at least 4 weeks before joining, meaning no worsening symptoms and no need for extra antibiotic treatment during that time - People who have been diagnosed with bronchiectasis (a lung condition i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04580368 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have signed a consent form (and an assent form where required for younger participants) - People who are willing and able to attend study visits and follow the study requirements - People who are male or female, aged 6 years or older, and within the age range appr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04700358 · University Hospital of Cologne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇩🇪 DE

Who might be able to join this trial: - Adults aged 18 years or older - People who are able to give their own consent to participate - People with a blood pressure reading within a normal range (top number between 100–150, bottom number below 90) - People with a breathing rate of fewer than 20 breaths per minute - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04731272 · University of Pennsylvania Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older at the time of giving consent, of any gender. - People with a confirmed diagnosis of cystic fibrosis (CF), based on a sweat test or genetic testing that meets recognised CF diagnostic standards. - People whose CF has caused their pancreas to stop working p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04732910 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇩🇪 DE

Who might be able to join this trial: - You and your cystic fibrosis doctor have together decided that you should start a type of treatment called a CFTR modulator therapy - You have read and signed a consent form agreeing to take part in the study (and if applicable, a separate assent form has also been signed) Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04793867 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇺🇸 US

**Who might be able to join this trial:** *For people with Cystic Fibrosis (CF):* - You have been diagnosed with CF, confirmed by a sweat chloride test result above 60 mMol/l - You have two known CF-causing gene changes, or you have symptoms/organ effects related to CF - You are at least 5 years old - You receive your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05017766 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇭 CH

**Who might be able to join this trial:** - You have a confirmed urinary tract infection (UTI), pneumonia (including if you have had a lung transplant or have cystic fibrosis), or a serious deep-seated infection caused by one of these specific bacteria: *E. coli*, *Klebsiella* species, *S. aureus*, or *P. aeruginosa*...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05099939 · Institut de Recherches Cliniques de Montreal Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇦 CA🇫🇷 FR

Who might be able to join this trial: - You have cystic fibrosis - You are 18 years of age or older - You have agreed to take part by giving your informed consent Who may not be able to join: - You are currently taking medication to treat diabetes - You have previously had a lung or liver transplant - You are already...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05200429 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - You have been prescribed a cystic fibrosis medication called a CFTR modulator and are planning to start taking it within the next 30 days, or you are planning to switch to a different CFTR modulator within the next 30 days - You are already registered in the Canadian Cystic Fibro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05248230 · 4D Molecular Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** **Primary Study:** - Adults aged 18 or older - People with a confirmed diagnosis of cystic fibrosis (CF) with lung disease, shown by a sweat chloride test result of 60 mmol/L or higher, and either two CF gene mutations or one CF gene mutation with signs of CF lung disease - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05279040 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with cystic fibrosis (CF) and have at least one copy of a specific gene change called F508del. - People whose doctor has planned to start them on the medication Trikafta within 30 days of joining the study. - People aged 19 years or older. - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05289245 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2032
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Cystic Fibrosis (CF) based on official World Health Organization guidelines - You have been in a stable condition with no respiratory infections for about 4 weeks before joining - You (or your parent/guardian if applicable) are willing and able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05501587 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with cystic fibrosis (CF), shown either by a sweat test result of 60 or above, or by having two CF-causing gene changes identified through genetic testing - You have been diagnosed with another type of lung disease by a doctor - You are a healthy person wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05504837 · Krystal Biotech, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be willing and able to read, sign, and follow the study's consent forms and instructions - You must be 18 years old or older when you sign the consent form - You must have a confirmed diagnosis of cystic fibrosis (CF), shown by symptoms plus either a sweat chloride t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05517655 · Children's Hospital Medical Center, Cincinnati Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - You (or your child's legal guardian) must be willing and able to give written permission to take part in the study. - You must be willing to attend all scheduled study visits and follow the study's requirements. - The child must be between 6 and 8 years old at the time of the...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05548283 · Chris Goss Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 31 May 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are 6 years of age or older (any gender) - You have been formally diagnosed with cystic fibrosis (CF) - Your doctor plans to treat your current CF lung flare-up with a 14-day course of antibiotics given through a vein (IV) - You have had at least one positive test result...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05723445 · Rhode Island Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People with a diagnosis of cystic fibrosis (CF) confirmed through genetic testing - People whose pancreas does not produce enough digestive enzymes, requiring them to take enzyme replacement medication - People who meet at least one of the foll...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05766774 · Emory University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have a confirmed diagnosis of cystic fibrosis (CF) - People who are 18 years of age or older - People whose estimated daily added sugar intake is more than 16 teaspoons, based on a dietary questionnaire completed during screening Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05783869 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with bronchiectasis (a lung condition where the airways are permanently widened) and have no other health conditions apart from possibly heart or blood vessel-related conditions. Who may not be able to join: - You do not wish to take part in the study. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05818319 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇰 DK

Who might be able to join this trial: - You are 18 years old or older and have cystic fibrosis (CF). - Your kidneys are working well, as measured by a standard kidney function test (confirm with trial site). - You are able to understand the study information and agree to take part on your own free will. Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05860803 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a Mayo Clinic patient who has been diagnosed with Non-Cystic Fibrosis Bronchiectasis (a lung condition causing widened, damaged airways), confirmed through your medical history, breathing tests, and a detailed CT scan. - Your condition is currently stable, meaning you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05937815 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 September 2026
🇫🇷 FR

Who might be able to join this trial: - People who have cystic fibrosis, confirmed by a sweat test result above 60 mmol/l - People who carry at least one copy of the DeltaF508 gene mutation associated with cystic fibrosis - People whose ongoing care is provided by a cystic fibrosis centre that is part of this study - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05982795 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 99 years old (inclusive) - You speak English - You have been diagnosed with cystic fibrosis (CF), confirmed through genetic testing along with a doctor's assessment and/or a sweat test - You receive your CF care at the New Hampshire Cystic Fibrosis Center -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05998629 · Milton S. Hershey Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older and able to sign and date a consent form yourself - You have been diagnosed with cystic fibrosis, OR you are a healthy volunteer with no cystic fibrosis diagnosis - You can understand and speak English Who may not be able to join: - You have a medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06032273 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - You are a family member or loved one who cares for someone with cystic fibrosis (CF) who is already taking part in the main "Lung Transplant READY CF 2" study, or - You are a person with cystic fibrosis (CF) who is already enrolled in the main "Lung Transplant READY CF 2" study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06045702 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - Male patients who are over 18 years of age - People without a genetic condition who are already scheduled to have surgery to collect sperm from the epididymis (a small organ attached to the testicle) - People diagnosed with cystic fibrosis or a condition where the vas deferen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06057714 · University of North Carolina, Chapel Hill Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have never smoked, or who smoked very little (fewer than 10 pack-years total) and have not smoked at all in the past year - People who have been diagnosed with cystic fibrosis through standard testing (such as a sweat test...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06066723 · University of North Carolina, Chapel Hill Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 6 and 17 years old - You are a non-smoker and do not vape - (For the Cystic Fibrosis group) You have been diagnosed with Cystic Fibrosis (CF) - You do not use supplemental (extra) oxygen - You are able to do a breathing test called spirometry, your lung functi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06132048 · Ad scientiam Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2024
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with cystic fibrosis - You are enrolled in or covered by a Social Security program - You have read the information sheet and signed a consent form agreeing to take part - You own a personal smartphone running iOS version...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06163482 · University of Cincinnati Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cystic fibrosis - You are between 18 and 45 years old - You are male or female, of any race or ethnicity - You are currently taking a highly effective CFTR modulator therapy (a type of medication used to treat cystic fibrosis) **Who may not be ab...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06216704 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - You are between 13 and 20 years old - You have cystic fibrosis with pancreatic insufficiency (meaning your pancreas does not produce enough digestive enzymes) - Your treatment plan, including any CFTR modulator medications, has stayed the same for the past three months - If you h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06237335 · ReCode Therapeutics Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 30 August 2026
🇫🇷 FR🇳🇱 NL🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** *Part 1 (Healthy Volunteers):* - You are a healthy adult (male or female) between 18 and 55 years old - You weigh at least 50 kg and your Body Mass Index (BMI) falls between 16 and 32 - Your lung function test shows your lungs are working at least 80% as well as expected for s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06242795 · University of North Carolina, Chapel Hill Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are able to give informed consent to participate - People who have been diagnosed with bronchiectasis (a lung condition involving widened airways), confirmed by a CT scan of the chest, affecting at least 2 sections of the lung, with at least one a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06274840 · Pilar Azevedo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇵🇹 PT

Who might be able to join this trial: - People who have cystic fibrosis, of any age, with any form of the condition, including those who have had a transplant or are at any stage of the disease, and who agree to take part Who may not be able to join: - People who do not wish to give their consent to take part in the t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06284577 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇳🇴 NO

Who might be able to join this trial: **For Part 1 of the trial:** - People with a type of cystic fibrosis gene mutation that is eligible for treatment with a specific combination therapy called ETI - Children aged 2 to 18 years (most participants are expected to be aged 2 to 6 years) - Children who are already regist...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06296394 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cystic fibrosis, confirmed by a sweat test or genetic testing - You have become a parent for the first time (including as a foster parent, step parent, adoptive parent, or legal guardian) to a child under 5 years old within the last 180 days Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06302270 · Region Stockholm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2034
🇸🇪 SE

Who might be able to join this trial: - Women who have cystic fibrosis, are pregnant, and are being treated with the medication Kaftrio - Newborn babies born to women who meet the above criteria Who may not be able to join: - There are no listed exclusion criteria for this trial Important: Always verify eligibility w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313827 · University of Valencia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with cystic fibrosis - Families who have access to a device that connects to the internet - People whose device has a working camera and microphone - People who have not had a cystic fibrosis flare-up or worsening of symptoms in the last 30 days Wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06339593 · Children's Hospital Medical Center, Cincinnati Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to provide written agreement to take part (or have a legal guardian provide this on their behalf) - People who have been taking a highly effective CF modulator medication (such as Trikafta) for more than 30 days - People who are willing and abl...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06356246 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇫🇷 FR

"Who might be able to join this trial: - People who are over 18 years old - People who have been diagnosed with cystic fibrosis - People who speak and understand French well enough to read and understand the study information documents - People who do not object to taking part in the study Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06364176 · University of Kansas Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cystic fibrosis - People aged 12 years or older - People who have been taking the medication elexacaftor/tezacaftor/ivacaftor (also known as Trikafta) consistently for at least 90 days before joining the trial - People whose sweat chloride...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06368804 · Centre Hospitalier Intercommunal Creteil Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 March 2025
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with bronchiectasis (a lung condition) confirmed by a chest CT scan - People who have had a recent respiratory sample (such as sputum) test positive for a bacteria called *Pseudomonas aeruginosa* (PA) within the last 3 mont...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06370962 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 October 2025
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with cystic fibrosis - Children and young people aged between 2 years and 17 years and 11 months - Those who have been receiving the CFTR modulator medication Kaftrio-Kalydeco for at least 2 months - Those who are being cared for at one of the Cysti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06429176 · SpliSense Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: **Cohorts 1–3 (without CFTR modulator therapy)** - People with a diagnosis of cystic fibrosis (CF) who carry a specific genetic mutation called 3849+10 Kb C->T on at least one copy of the CFTR gene, confirmed by a certified genetic testing laboratory. - People with a body mass ind...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06449677 · Jaeb Center for Health Research Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - People who are 14 years of age or older at the time of signing the consent form - People who are able to give informed consent (for those under 18, a parent or guardian must also agree) - People who have been diagnosed with cystic fibrosis (CF), confirmed by a sweat test showing...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06457451 · University Hospital, Tours Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with cystic fibrosis - People who have been taking the combination medication Elexacaftor-Tezacaftor-Ivacaftor (also known as Kaftrio or Trikafta) for at least 6 months - People who are enrolled in a social...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06487273 · Physio-Assist Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇫🇷 FR🇩🇪 DE🇵🇱 PL🇵🇹 PT Reunion🇬🇧 GB

**Who might be able to join this trial:** - Adults aged 18 or older (male or female) - People with a confirmed diagnosis of bronchiectasis (not caused by cystic fibrosis), confirmed by a CT scan - People who regularly and consistently produce mucus/phlegm - People whose condition is currently stable — meaning at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06504589 · Nicole Hamblett Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 August 2029
🇺🇸 US

**Who might be able to join this trial:** - You (or your legal guardian) are willing and able to sign a consent form agreeing to take part in the study - You are willing and able to attend all scheduled study visits and follow the study requirements - You are 12 years of age or older at your first study visit - If you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06507956 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are an adult (of legal age, male or female) - You have cystic fibrosis and are regularly seen at the cystic fibrosis centre at Hôpital Lyon Sud - You are willing to take part in the study voluntarily **Who may not be able to join:** - People who, due to other health cond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512064 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇺🇸 US

Who might be able to join this trial: - People aged between 8 and 70 years old - People who are able to perform breathing tests called spirometry and oscillometry - People who have given their signed consent to participate (for children, both the child's agreement and a parent or guardian's consent are required) - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06526923 · Spirovant Sciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 65 years old (inclusive) - You have been diagnosed with cystic fibrosis (CF) - Your lung function test result (a breathing test called FEV1) falls between 50% and 100% of the expected value - Your blood oxygen level is at least 94% when measured by a finger...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06546943 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇺🇸 US

Who might be able to join this trial: - People aged 6 to 25 years old - People with a confirmed diagnosis of cystic fibrosis, based on sweat chloride test results and/or two known cystic fibrosis gene mutations - People who have access to a smartphone and/or internet connection and are able to attend remote video appoi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06559150 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Je... Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 24 September 2027
🇮🇹 IT🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Men who agree to use contraception during the study and for at least 30 days after their last dose of study medication - Women who are not pregnant, not breastfeeding, and either cannot become pregnant or agree to use contraception during the study and for at least 30 days a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06560463 · Medical College of Wisconsin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇺🇸 US

Who might be able to join this trial: - You are an adult who has been diagnosed with cystic fibrosis (CF) and are a patient at the Froedtert Multidisciplinary CF Clinic. - Your blood sugar levels are either normal or slightly higher than normal (but not diabetic), based on a sugar-tolerance test done in 2024. - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06587126 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇺🇸 US

**Who might be able to join this trial:** *For children with Cystic Fibrosis:* - The child has been diagnosed with Cystic Fibrosis, confirmed by having 2 known CF gene changes and/or a sweat test result above 60 mmol/L - The child is between 1 and 18 years old - The child is in a stable state of health at the time of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06595420 · University of Virginia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** **Outpatient group (people with Cystic Fibrosis attending clinic):** - People who have been diagnosed with Cystic Fibrosis - People who are older than 30 years of age - People who are able to give their own informed consent to participate **Inpatient group (people with Cystic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06599892 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇫🇷 FR

Who might be able to join this trial: - People aged 6 and older who have cystic fibrosis and have been receiving a treatment called CFTRmHE for at least 12 months - People aged over 6 who have cystic fibrosis but are not eligible for CFTRmHE treatment - Family members of cystic fibrosis patients who are under 18 years...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06603246 · Genentech, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 November 2027
🇺🇸 US

Who might be able to join this trial: - Lung function testing (spirometry) during screening shows FEV1 (a measure of how much air can be breathed out) at 40% or more of the expected value for a person of that age and size - The person is able to correctly use the study inhaler device, as judged by the study doctor - Th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06616857 · Nemours Children's Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You are between 13 and 25 years old - You have been diagnosed with cystic fibrosis (CF) or a related condition - Your health is currently stable, meaning your lung function is above a certain level and you are not having a CF flare-up at the time of joining - You can speak and re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06642610 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People with cystic fibrosis (CF) who are between 12 and 55 years old. - People with CF who do not have diabetes, or who have been found to have prediabetes (based on a specific sugar test called an OGTT and a blood test called HbA1c). - People who are willing to wear a small...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06654752 · University of Washington, the Collaborative Health Studies Coordinatin... Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers aged 6 to under 19 years old (for the main group and the non-HEMT group), or children aged 3 to under 6 years old (for the preschool group) - You have been diagnosed with cystic fibrosis (CF), confirmed by a high salt level in a sweat test or by having...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06660992 · Haisco Pharmaceutical Group Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older and have a healthy body weight (BMI of 18.0 or above) - A detailed lung scan (HRCT) has confirmed that you have bronchiectasis (a condition causing widened, damaged airways) affecting one or more areas of your lungs, with symptoms such as lon...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06683092 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: **For the Mental Health arm of the trial (RETRIAL-Mental Health):** - People with cystic fibrosis (CF) aged 6 years and older (for children under 12, a caregiver will complete the daily diaries and surveys on their behalf) - People whose doctor has determined they are eligible for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06747858 · Arcturus Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have a confirmed diagnosis of Cystic Fibrosis - You are either not eligible for CFTR modulator therapy (a specific type of Cystic Fibrosis medication), or you have not been taking CFTR modulators for at least 60 days before the study begins — for example, because of side...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06775340 · Jiangsu HengRui Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive), either male or female - If you are female, you weigh at least 45 kg (about 99 lbs); if you are male, you weigh at least 50 kg (about 110 lbs) - A special lung scan (HRCT) has shown bronchiectasis (widening/damage of the airways...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06797206 · Royal Brompton & Harefield NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇬🇧 GB

**Who might be able to join this trial:** **'Mama' sub-study (for people with CF who are pregnant or planning pregnancy):** - A person who is willing and able to give written agreement to take part in the study - A person who is already a patient at the Royal Brompton Hospital CF Reproductive and Maternal Health Servi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06810167 · Massachusetts General Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with cystic fibrosis, confirmed either through a sweat chloride test or genetic testing. - People who have cystic fibrosis-related constipation (CFrC), meaning they have experienced at least 2 of the following symptoms for at least 3 months, with th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06836453 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇧🇪 BE

Who might be able to join this trial: - People who are healthy volunteers - People who carry the cystic fibrosis gene but do not have the condition themselves (for example, parents of someone with cystic fibrosis) - People who have been diagnosed with cystic fibrosis or a condition classified as cystic fibrosis-related...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06837181 · Jaeb Center for Health Research Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give written consent to take part (or have a legal representative who can do this on their behalf) - Adults who are able to make their own decisions and give consent independently - People who are willing and able to follow the study requir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915961 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 October 2025
🇪🇬 EG

Who might be able to join this trial: - Children and young people who have been diagnosed with Cystic Fibrosis (CF), confirmed by a sweat test showing high salt levels (≥60 milliequivalents per litre) and/or having two CF-related gene changes - Participants must be 6 years old or older - Participants must have a breath...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06940531 · Alexander Horsley Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇬🇧 GB

**Who might be able to join this trial:** **For adults with cystic fibrosis (CF):** - You have a confirmed diagnosis of CF, based on genetic testing and/or a sweat test result above 60mmol/L, along with symptoms consistent with CF - You are 16 years old or older and receive your CF care at a UK Adult CF Centre - You h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06950892 · University of Pennsylvania Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cystic fibrosis (CF) according to standard guidelines — this can be confirmed through genetic testing, a sweat chloride test, or a diagnosis made by a doctor at a CF-accredited centre. - You are 18 years old or older. - You are able to attend stud...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06984679 · Izmir Democracy University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
Turkey (Türkiye)

Who might be able to join this trial: **For children and adolescents with cystic fibrosis:** - Children and adolescents aged 6 to 18 years - People who have been diagnosed with cystic fibrosis - People whose condition has been medically stable for at least 3 weeks - People who are able to cooperate with the required m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06985225 · University of Kansas Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed by a doctor with a lung condition that causes mucus buildup, such as cystic fibrosis, severe asthma, chronic obstructive pulmonary disease (COPD), or bronchiectasis (non-cystic fibrosis type), for more than 1 year...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995651 · University of Pennsylvania Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to sign a consent form and take part in all study activities for the full duration of the trial. - People aged 18 or older at the time of consent. - People with a confirmed diagnosis of cystic fibrosis (CF), based on a sweat test or genetic te...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06998043 · BiomX Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have cystic fibrosis with a long-term lung infection caused by a bacteria called *Pseudomonas aeruginosa*, who are either taking inhaled antibiotics as part of their usual care or not taking inhaled antibiotics at all - People aged 18 or older - People whose lung f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07031323 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cystic fibrosis (CF) - You are 18 years of age or older - You have been prescribed a CF medication (called a CFTR modulator) that you take twice a day - You are able to speak and read English - You have regular access to an iOS or Android tablet or sm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07048574 · State University of New York at Buffalo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

Who might be able to join this trial: - The child has a confirmed diagnosis of Cystic Fibrosis (CF) and is actively receiving care from a CF care team at a participating trial site - The child is between 18 months and 11 years of age - The family speaks English and/or Spanish - A parent or legal guardian is willing and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07071324 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have an official diagnosis of Cystic Fibrosis (CF) recorded in your medical records - You have scored higher than 4 on a fatigue measurement scale called the Fatigue Severity Scale (confirm with trial site) - You have access to a smartphone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07102043 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with Cystic Fibrosis Related Diabetes (CFRD) - People aged between 21 and 75 years old at the time of signing the consent form - People with a body mass index (a measure of body weight relative to height) between 19 and 50, or between 17 and 48...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07148739 · Arkansas Children's Hospital Research Institute Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have been formally diagnosed with cystic fibrosis (CF) and whose specific CF gene type (genotype) is known - People who are 2 years of age or older - People (or their legal guardian) who are able to give written agreement to take part in the trial - People who have bee...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07192679 · Sheffield Teaching Hospitals NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇬🇧 GB

**Who might be able to join this trial:** - People who have a confirmed diagnosis of cystic fibrosis (CF), supported by two known CF-causing gene changes, plus either a positive sweat test result (above 60 mmol/L, taken before starting CF modulator treatment) or a clinical assessment by a senior CF doctor confirming t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07202910 · Sahlgrenska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇸🇪 SE

Who might be able to join this trial: - Children aged 0 to 18 years who are already scheduled to have a liver biopsy at Queen Silvia Children's Hospital as part of their normal medical care - Children who have a suspected or confirmed liver condition of any kind - Children (and/or their parents) who agree to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07223255 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Children aged 3 and older (both boys and girls) who have been diagnosed with cystic fibrosis - Children whose nutritional status, measured by a standard weight-for-height score called BMI Z-score, is at -1 or higher (meaning not considered malnourished) - Children whose cyst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07245407 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 July 2027
🇨🇳 CN

**Who might be able to join this trial:** **Healthy volunteer group:** - You are 30 years of age or older **Bronchiectasis patient group:** - You are 18 years of age or older - You have been diagnosed by a doctor with bronchiectasis, supported by symptoms (such as long-term cough and daily mucus production) and a che...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07274631 · CHU de Reims Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2030
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years of age or older - You are currently being monitored or treated for one of the following lung conditions: asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung diseases - Healthy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07283770 · Vertex Pharmaceuticals Incorporated Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 19 November 2026
🇺🇸 US

Who might be able to join this trial: - Your body mass index (BMI) must be between 18.0 and 32.0 (this is a measure of body weight relative to height — you can check yours online with a BMI calculator) - You must weigh more than 50 kilograms (approximately 110 pounds) - You must be male or female and not able to become...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07289100 · Papworth Hospital NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇬🇧 GB

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with cystic fibrosis (confirmed through a gene test or a sweat test) or a lung condition called non-CF bronchiectasis (confirmed by a CT scan) - You are currently a patient under the care of Royal Papworth Hospital - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07289464 · Reistone Biopharma Company Limited Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been fully informed about the trial and have given their written agreement to participate. - Healthy adults between 18 and 55 years of age (men and women). - People whose body weight is at least 50 kg (for men) or at least 45 kg (for women), and whose Body Mass In...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07303621 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 August 2027
🇫🇷 FR

Who might be able to join this trial: - Children between 2 and 17 years old - Children who have been diagnosed with Cystic Fibrosis - Children who are currently being treated with the medication combination Elexacaftor/Tezacaftor/Ivacaftor (sold under the brand names Trikafta® or Kaftrio®) Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07312734 · Chris Goss Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - People who are 16 years of age or older at the time of the study visit - People who have a documented diagnosis of cystic fibrosis (CF) - People who are able to cough up mucus (sputum) from their lungs - People whose lung function test (called FEV1) shows a result of 30% or highe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07314229 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 February 2027
🇫🇷 FR

Who might be able to join this trial: - You can be male or female - You must be 18 years old or older - You have been diagnosed with cystic fibrosis - You are receiving care at the CRCM centre in Lille or Créteil (France) - You are currently being treated with a medication called ETI (confirm with trial site for full n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07342920 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have a confirmed diagnosis of cystic fibrosis - People who regularly attend follow-up appointments at the Strasbourg Adult Cystic Fibrosis Center Who may not be able to join: - People who have had a double lung transplant for cystic fib...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07363304 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2028
🇮🇹 IT

Who might be able to join this trial: - People with cystic fibrosis (CF) of any age who are about to start a specific combination therapy called ETI (elexacaftor/tezacaftor/ivacaftor), as permitted under Italian medicines regulations - People who are being cared for at one of the participating CF treatment centres in I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07436351 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have already been diagnosed with cystic fibrosis - You have scored above 4 on a depression questionnaire (PHQ-9) or above 4 on an anxiety questionnaire (GAD-7), which are standard screening tools your doctor may use **Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07437105 · Vertex Pharmaceuticals Incorporated Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 23 March 2027
🇺🇸 US

Who might be able to join this trial: - People with a body mass index (BMI) between 18.0 and 32.0 (a measure of body weight relative to height) - People who weigh more than 50 kilograms (approximately 110 pounds) - Men, and women who are not able to become pregnant Who may not be able to join: - People who have had a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07450547 · Anagram Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are aged 12 or older (if in the US) or 18 or older (if in the EU) - You have a confirmed and documented diagnosis of cystic fibrosis (CF) - You have been diagnosed with severe exocrine pancreatic insufficiency (EPI), meaning your pancreas is not releasing enough digestiv...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07484607 · Alexander Horsley Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇬🇧 GB

**Who might be able to join this trial:** - People who have a confirmed diagnosis of cystic fibrosis (CF), based on genetic testing showing two CF-causing gene changes plus symptoms of CF, or at least one CF-causing gene change plus a sweat chloride test result above 60mmol/L plus symptoms of CF. - People who are curr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07508904 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇵🇰 PK

Who might be able to join this trial: - Children and teenagers between 6 and 18 years old - People who have been diagnosed with cystic fibrosis - People whose condition is currently stable - People who are physically able to take part in exercise - People whose parent or legal guardian has given consent for them to par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07547436 · Sanofi Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 October 2027
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 80 years old at the time of signing the consent form - You have a history of symptoms consistent with non-cystic fibrosis bronchiectasis, such as a long-term productive cough and/or repeated chest infections - You have had at least 2 chest infection episode...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07569419 · University of Nottingham Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who are willing and able to give their agreement to take part after being fully informed about the study - People aged between 18 and 60 years - People who are not currently taking any medications, apart from certain antidepressants (SSRIs or low-dose tricyclic antidep...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07599839 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇪🇬 EG

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with non-cystic fibrosis bronchiectasis (a lung condition causing widened, damaged airways — but not caused by cystic fibrosis), confirmed by a clinical assessment and a detailed CT scan of the chest - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07599969 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a lung condition called bronchiectasis (not caused by cystic fibrosis), confirmed by a detailed type of chest scan called an HRCT - You are currently receiving care at Assiut University Hospitals — either as an o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07616375 · Haisco Pharmaceutical Group Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 10 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You previously took part in the HSK31858-301 study, completed the randomisation process, and received at least the first dose of the study medication - If you regularly use long-acting br...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07629986 · Fondation Ildys Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with cystic fibrosis, confirmed by a sweat test and/or genetic testing - You have been taking the medication elexacaftor/tezacaftor/ivacaftor (also known as ETI or Kaftrio/Trikafta) for at least 3 months - You are 12 years old or older - You (and your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07709494 · Revagenix, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** *For healthy participants:* - Men and women between 18 and 55 years old who are in good general health - People with a body mass index (a measure of body weight relative to height) between 18 and 32 - People whose lungs are working at 80% or more of the expected level, based o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07729787 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇵🇰 PK

Who might be able to join this trial: - People who have been diagnosed with cystic fibrosis, confirmed by a sweat test or genetic testing. - Children between the ages of 6 and 12 years old. - Children whose condition is currently stable, meaning no serious lung flare-ups in the past 4 weeks. Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Cystic Fibrosis. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Cystic Fibrosis Australia (CFA) is the national body for people with cystic fibrosis.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.